Niall C Tebbutt
Overview
Explore the profile of Niall C Tebbutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
6268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burge M, Espinoza D, Sjoquist K, Siu D, Mercieca-Bebber R, Chantrill L, et al.
Clin Colorectal Cancer
. 2025 Jan;
PMID: 39779412
Background: Panitumumab (pan) plus chemotherapy is a preferred first-line therapy for unresectable RAS and BRAF wild type metastatic colorectal cancer (mCRC). Older patients may not be suitable for combination regimens....
2.
Depauw L, Townsend A, Karapetis C, Roy A, Wigg A, Tebbutt N, et al.
Expert Rev Anticancer Ther
. 2024 Dec;
25(1):41-53.
PMID: 39718339
Introduction: Resection of primary tumor and liver metastases is the gold standard for colorectal cancer with liver-only metastases (CRLM). Although treatment options have expanded to enable conversion of unresectable to...
3.
Tran K, Kumari A, Raghu D, Cox D, Goh S, Perini M, et al.
iScience
. 2024 Sep;
27(9):110754.
PMID: 39280606
The presence of precursor to exhausted (T) CD8 T cells is important to maintain robust immunity following treatment with immune checkpoint inhibition (ICI). Impressive responses to ICI are emerging in...
4.
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg J, et al.
Eur J Cancer
. 2024 Jun;
207:114160.
PMID: 38896997
Background: The liver is the most frequent site of metastases in colorectal cancer (CRC). This study aimed to assess the response rate and survival outcomes in metastatic CRC patients with...
5.
Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al.
J Clin Oncol
. 2024 May;
42(17):2080-2093.
PMID: 38723227
Purpose: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients...
6.
Gupta A, OCallaghan C, Zhu L, Jonker D, Wong R, Colwell B, et al.
J Natl Cancer Inst
. 2024 Apr;
116(8):1313-1318.
PMID: 38656931
Introduction: Although contact days-days with health-care contact outside home-are increasingly adopted as a measure of time toxicity and treatment burden, they could also serve as a surrogate of treatment-related harm....
7.
Allan Z, Witts S, Wong D, Lee M, Tie J, Tebbutt N, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300546.
PMID: 38513167
Purpose: Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal tumor DNA (ptDNA) is tumor-derived...
8.
Jenkins L, Luk I, Chionh F, Tan T, Needham K, Ayton J, et al.
Cell Death Dis
. 2024 Mar;
15(3):183.
PMID: 38429301
Metastatic BRAF colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAF inhibitor encorafenib in combination with the EGFR inhibitor...
9.
Tan T, Mouradov D, Lee M, Gard G, Hirokawa Y, Li S, et al.
Cell Rep Med
. 2023 Dec;
4(12):101335.
PMID: 38118423
Predictive drug testing of patient-derived tumor organoids (PDTOs) holds promise for personalizing treatment of metastatic colorectal cancer (mCRC), but prospective data are limited to chemotherapy regimens with conflicting results. We...
10.
Jefford M, Emery J, Martin A, De Abreu Lourenco R, Lisy K, Grunfeld E, et al.
EClinicalMedicine
. 2023 Dec;
66:102346.
PMID: 38094163
Background: SCORE is the first randomised controlled trial (RCT) to examine shared oncologist and general practitioner (GP) follow-up for survivors of colorectal cancer (CRC). SCORE aimed to show that shared...